Futura Medical Announces Collaboration with Labatec Pharma to Commercialise MED3000 in the Gulf and Middle East Region

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into a licensing agreement with Labatec Pharma (“Labatec”), a Swiss-based specialty pharma Company focused on commercialisation in Europe and the Middle East and North Africa (“MENA”) regions, for the rights to exclusively commercialise the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment MED3000, in the Gulf Co-operation Council (“GCC”) region as well as Jordan, Lebanon and Iraq.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH